Fortress Biotech - FBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.67
  • Forecasted Upside: 566.67%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.05
▼ -0.01 (-0.49%)

This chart shows the closing price for FBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fortress Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBIO

Analyst Price Target is $13.67
▲ +566.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Fortress Biotech in the last 3 months. The average price target is $13.67, with a high forecast of $26.00 and a low forecast of $5.00. The average price target represents a 566.67% upside from the last price of $2.05.

This chart shows the closing price for FBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Fortress Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
7/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/16/2024Roth MkmReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/19/2024Alliance Global PartnersInitiated CoverageBuy$5.00
3/15/2024Roth MkmInitiated CoverageBuy$10.00
11/29/2023Roth MkmLower TargetBuy ➝ Buy$30.00 ➝ $15.00
8/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
5/16/2023Cantor FitzgeraldLower Target$90.00 ➝ $75.00
4/6/2023BenchmarkReiterated RatingSpeculative Buy$75.00
4/4/2023Roth CapitalReiterated RatingBuy
4/3/2023Cantor FitzgeraldReiterated RatingOverweight
8/4/2022LADENBURG THALM/SH SHInitiated CoverageBuy$90.00
7/14/2022B. RileyLower TargetBuy$120.00 ➝ $90.00
5/13/2022Cantor FitzgeraldReiterated RatingBuy$90.00
3/29/2022Roth CapitalReiterated RatingBuy
12/7/2021UBS GroupReiterated RatingPositive$300.00
11/17/2021B. RileyReiterated RatingBuy
10/8/2021HC WainwrightReiterated RatingBuy$150.00
9/29/2021B. RileyReiterated RatingBuy$120.00
6/17/2021B. RileyLower TargetAccumulate ➝ Buy$135.00 ➝ $120.00
4/20/2021Roth CapitalBoost TargetBuy$67.50 ➝ $75.00
4/5/2021B. RileyReiterated RatingBuy$120.00 ➝ $135.00
4/1/2021Cantor FitzgeraldReiterated RatingOverweight
2/26/2021HC WainwrightReiterated RatingBuy$150.00
2/17/2021Dawson JamesBoost TargetBuy$240.00 ➝ $315.00
12/17/2020B. RileyReiterated RatingBuy
10/13/2020Roth CapitalLower TargetBuy$75.00 ➝ $71.25
10/12/2020HC WainwrightLower TargetBuy$165.00 ➝ $150.00
10/2/2020BenchmarkInitiated CoverageBuy$135.00 ➝ $135.00
8/21/2020B. RileyBoost Target$90.00 ➝ $120.00
8/12/2020B. RileyReiterated RatingBuy$90.00
5/18/2020B. RileyReiterated RatingBuy$90.00
5/8/2020HC WainwrightReiterated RatingBuy$165.00
3/17/2020Cantor FitzgeraldReiterated RatingOverweight
3/13/2020B. RileyLower TargetBuy$135.00 ➝ $90.00
2/12/2020Cantor FitzgeraldInitiated CoverageOverweight$90.00
12/18/2019B. RileyInitiated CoverageBuy$135.00
(Data available from 12/7/2019 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Fortress Biotech logo
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Read More

Today's Range

Now: $2.05
Low: $1.97
High: $2.13

50 Day Range

MA: $1.76
Low: $1.43
High: $2.30

52 Week Range

Now: $2.05
Low: $1.36
High: $4.43

Volume

829,413 shs

Average Volume

542,121 shs

Market Capitalization

$56.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Fortress Biotech?

The following Wall Street sell-side analysts have issued research reports on Fortress Biotech in the last twelve months: Alliance Global Partners, Cantor Fitzgerald, HC Wainwright, Roth Mkm, and StockNews.com.
View the latest analyst ratings for FBIO.

What is the current price target for Fortress Biotech?

0 Wall Street analysts have set twelve-month price targets for Fortress Biotech in the last year. Their average twelve-month price target is $13.67, suggesting a possible upside of 566.7%. HC Wainwright has the highest price target set, predicting FBIO will reach $26.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $5.00 for Fortress Biotech in the next year.
View the latest price targets for FBIO.

What is the current consensus analyst rating for Fortress Biotech?

Fortress Biotech currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FBIO will outperform the market and that investors should add to their positions of Fortress Biotech.
View the latest ratings for FBIO.

What other companies compete with Fortress Biotech?

How do I contact Fortress Biotech's investor relations team?

Fortress Biotech's physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected]. The official website for Fortress Biotech is www.fortressbiotech.com. Learn More about contacing Fortress Biotech investor relations.